Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
about
New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisonsDabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of SubgroupsESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryDirect thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationFactor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillationEducational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillationStroke prevention in atrial fibrillation: latest clinical trials and guidelinesManagement of bleeding in patients treated with direct oral anticoagulantsDabigatran approaching the realm of heparin-induced thrombocytopeniaVitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequencesManagement of antithrombotic therapy during cardiac implantable device surgeryComparative risk impact of edoxaban in the management of stroke and venous thromboembolismDirect-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansThe Mechanism of and Preventive Therapy for Stroke in Patients with Atrial FibrillationHow we treat bleeding associated with direct oral anticoagulantsAsian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral AnticoagulantsNon-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesEdoxaban in venous thromboembolism and stroke prevention: an appraisalUse of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart LesionsReversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumabEmerging Tools for Stroke Prevention in Atrial FibrillationChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewImproved Cardiovascular Disease Outcomes in Older AdultsManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyProfiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differencesCurrent Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric PopulationNovel oral anticoagulants and the 73rd anniversary of historical warfarinStroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsMonitoring anticoagulant therapy with new oral agentsThe evolution of anticoagulant therapyManaging atrial fibrillation in the very elderly patient: challenges and solutionsHow to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationAtrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectivesA review of the LARIAT device: insights from the cumulative clinical experienceStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsPerioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: an analysis of the implications for perioperative managementRisk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-AnalysisAtrial fibrillation in heart failure: what should we do?Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary careDirect Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities
P2860
Q21132464-0CC08021-6472-451D-9EF2-3FD562258581Q21284803-DF4A6BCF-EBB0-4ECC-A938-8ADDDC9081AEQ22241786-DBECD57E-71F2-411B-826E-8F9A3AADF6B5Q24197843-95C2024C-51D2-42AC-9E9C-C6BFDCABACC3Q24200497-7D211B67-83C8-4D4B-BDEB-F1D501C2B19EQ24202280-4EBB0F36-9F03-49ED-88D4-FD45A092B5DDQ24628390-5BE124C7-52C4-41B0-9303-F141FE478FB8Q26740258-88EC7F19-E356-49DB-AB81-84D509AB50CAQ26744261-29905258-1437-480A-98EB-7B3E73CEFC35Q26746062-B9CCA753-C581-4417-ACB9-0EBFAA906B27Q26746160-1D841D1F-D549-4090-9D6C-13B57A2E9807Q26746233-5B046304-3665-459A-BB29-6D6684A73E27Q26746917-0E17A949-A492-458E-BA9C-DEE3DFFB0B7CQ26747263-58914126-CA23-48D1-9D57-F9D49DA82C2EQ26748343-23A55BD7-A7EA-49E7-96F7-EF1ED567B46AQ26750467-7FBC8DAC-58CB-4EDB-9552-679BC8DA1C36Q26750767-61FE9FFE-8F40-4D91-8748-61C33E3DDFF8Q26751263-F986820A-DAF6-47D5-8FA8-C31E1A7C2564Q26764853-4D66D657-FBC2-4555-A8EA-3B3178333700Q26764882-1160EF6B-AF30-4383-A9A6-BFA425614B10Q26765023-646D9394-D535-4F17-9552-FC9699D02B18Q26765949-0FCCA585-8518-4B5A-9473-3756F2FB54D4Q26766094-4033BB25-9E1E-4E28-BA71-5D9AA677B59EQ26766303-4FE033F0-4A69-4693-92FF-03B3E48E9338Q26766354-CFB38580-D0B7-463F-A528-0FCA094F77DFQ26770402-E1517603-092E-40EA-8ACF-3DAF08336AF7Q26771544-59CD5144-5882-4520-95BE-55930B11D403Q26771564-3B916F35-56C2-4930-BF0E-3A9807E35778Q26771728-213E6765-22ED-44A6-8692-E2F89A87985CQ26771859-FE8C48E6-BA56-4DB0-9F33-B6D9D92629D6Q26775877-52E63CBF-3812-462C-8B75-EEBD9F8BE96AQ26776413-B2F3FDB8-297E-453A-BA6F-8199E08CCCCDQ26778659-69A87911-DBD9-4DF8-9EC2-D8773E0EE23EQ26781162-6D0ABD28-EBAD-4E21-A827-6B51D846F842Q26781181-4FB64B24-4C36-4E00-94ED-CBF7DDB11648Q26781790-66934328-5793-486E-AC0C-2063725720F9Q26783473-C4BA3F49-42F3-48DE-827A-7630B410E070Q26784426-F6665087-3432-45BC-AC63-525F44B19972Q26785480-C093E416-51B8-4981-8CCA-4795FA3A37BCQ26787046-DBC8ED07-71BE-4CCA-9B21-4267815B69B4
P2860
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
@ast
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
@en
type
label
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
@ast
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
@en
prefLabel
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
@ast
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
@en
P2093
P3181
P356
P1476
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
@en
P2093
Berkowitz SD
Breithardt G
Halperin JL
Mahaffey KW
P304
P3181
P356
10.1056/NEJMOA1009638
P407
P577
2011-09-08T00:00:00Z